SCHEMBL24124898

SCHEMBL24124898

CN1C(=O)CSc2ccc(C(=O)Nc3ccc(CN4CCCCCC4)cc3)cc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ HTT P42858 2/20 0.57
▸ OPRM1 P35372 1/20 0.57
▸ OPRD1 P41143 1/20 0.57
▸ TNF P01375 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ LMNA P02545 2/20 0.53
▸ GAA P10253 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ POLB P06746 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ MAPK1 P28482 4/20 0.51
▸ ESR1 P03372 1/20 0.51
▸ ESR2 Q92731 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124186 1.00 MAPT (0.57) MAPTSMN1; SMN2KMT2AMEN1HTT
SCHEMBL25926503 0.89 RAB9A (0.54) MAPTSMN1; SMN2KMT2AHTTTNF
SCHEMBL24124676 0.82 MAPT (0.55) MAPTSMN1; SMN2KMT2AMEN1HTT
SCHEMBL3597956 0.82 TRPV1 (0.75) TRPV1
SCHEMBL24124187 0.82 TRPV1 (0.67) KMT2AHTTTNFHPGDLMNA
SCHEMBL30270587 0.82 CYP1A2 (0.58) MAPTSMN1; SMN2KMT2AMEN1TP53
SCHEMBL25921866 0.82 CYP1A2 (0.58) MAPTSMN1; SMN2KMT2AMEN1TP53
SCHEMBL24124884 0.81 MAPT (0.64) MAPTSMN1; SMN2KMT2AMEN1HTT
SCHEMBL24124767 0.81 MAPT (0.53) MAPTSMN1; SMN2KMT2AMEN1HTT
SCHEMBL24124264 0.80 MAPT (0.57) MAPTSMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 MAPT 4492/4885SMN1; SMN2 4270/4885KMT2A 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback